- Conditions: Alzheimer's Disease; Schizophrenia
Interventions: Drug: amisulpride; Drug: amisulpride; Drug: amisulpride
Sponsors: Institute of Psychiatry, London; Institute of Psychiatry, London
Not yet recruiting - verified October 2011 - Condition: Alzheimer's Disease
Interventions: Drug: MABT5102A; Drug: MABT5102A; Drug: placebo; Drug: placebo
Sponsors: Genentech; Genentech
Recruiting - verified April 2012 - Condition: Alzheimer Disease
Interventions: Drug: gantenerumab; Drug: gantenerumab; Drug: placebo
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2012 - Condition: Alzheimer's Disease
Intervention: Drug: Solanezumab
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2012 - Condition: Alzheimer Disease
Intervention: Drug: Bapineuzumab 0.5 mg/kg
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2012 - Condition: Alzheimer Disease
Interventions: Drug: Bapineuzumab 0.5 mg/kg; Drug: Bapineuzumab 1.0 m/kg
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2012 - Condition: Alzheimer's Disease
Intervention:
Sponsors: Washington University School of Medicine; Washington University School of Medicine; National Institute on Aging (NIA)
Recruiting - verified October 2011 - Condition: Alzheimer Disease
Interventions: Drug: bapineuzumab; Drug: bapineuzumab; Drug: placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2012
 |
Join Clinical Trials for Alzheimer Disease in United Kingdom |
